Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:57:25 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:SAGE from 2023-04-27 to 2024-04-26 - 21 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-25 06:30U:SAGENews ReleaseSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
2024-04-17 06:30U:SAGENews ReleaseSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
2024-04-11 06:30U:SAGENews ReleaseSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
2024-02-28 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming March Investor Conferences
2024-02-14 06:30U:SAGENews ReleaseSage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
2024-01-31 06:30U:SAGENews ReleaseSage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
2024-01-02 06:30U:SAGENews ReleaseSage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
2023-12-14 06:30U:SAGENews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-12-14 06:30U:SAGENews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-11-08 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming November Investor Conferences
2023-11-07 06:30U:SAGENews ReleaseSage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-10-24 06:30U:SAGENews ReleaseSage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
2023-10-18 06:30U:SAGENews ReleaseSage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington ¢ € ™s Disease
2023-09-06 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming September Investor Conferences
2023-08-31 06:30U:SAGENews ReleaseSage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE ¢ „ ¢ Commercial Launch and Pipeline Advancement
2023-08-07 06:30U:SAGENews ReleaseSage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2023-08-04 22:45U:SAGENews ReleaseSage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
2023-08-04 22:42U:SAGENews ReleaseFDA Approves ZURZUVAE ¢ „ ¢ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
2023-06-05 06:30U:SAGENews ReleaseSage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-03 06:30U:SAGENews ReleaseSage Therapeutics to Present at Upcoming May Investor Conferences
2023-05-02 06:30U:SAGENews ReleaseSage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress